Dr. Steenblock’s Stem Cell Journey
Healing with stem cells: My journey
By David A. Steenblock, M.S., D.O.1
1The Steenblock Research Institute (San Clemente, California, USA)
There is a natural and rather ego-gratifying tendency among most of us doctors to believe “real” medicine began with our practice of it. Of course, the problem with this is that someone failed to inform historians and fix the history books which tell a decidedly different story!
I can illustrate this by taking a page from my own life and career – which is also the topic of this article, namely adult stem cells and their clinical application to turning the tables on various chronic diseases and medical conditions.
I first learned about the use of bone marrow stem cells as a young physician extern in the Department of Hematology & Oncology at the University of Washington in 1969. At the time I felt like stem cells were something hitherto hidden from most other doctors and that my associates and I were going to launch a new age of regenerative medicine with them. There was actually some good reason to think this. The particular program I was part of was directed by physician Edward Donnall (“Don”) Thomas whose illustrious career culminated in his being awarded the Nobel Prize in Physiology or Medicine with another physician, Joseph E. Murray, in 1990, for the development of cell and organ transplantation. It was Dr. Thomas who actually developed bone marrow transplantation as a treatment for leukemia. He and his team ultimately did over 4,000 human marrow transplants1.
However, as I discovered later on, stem cells were not exactly unknown to medicine…and the new age of regenerative medicine would dawn a little later than I originally anticipated.
It was actually in the year 1908 that the Russian histologist Alexander Maksimov (1874–1928) proposed the use of the term “stem cell” at a hematologic society congress held in Berlin, Germany2. He crafted this term to help describe something he had observed about blood; namely that all blood cells develop from a common precursor cell. This theory of common descent or the “unitarian theory of hematopoiesis” was based on years of extensive research by Dr. Maksimov. Other experimental work he did supported his contention that lymphocytes of the blood and lymph nodes are undifferentiated cells3.
But, like many developments in medicine, there was a great lag time between the discovery of stem cells and sufficient acceptance to spurn on additional exploration of their nature and possible medical uses. All told, things didn’t get really going until the 1950s into the 1960s. At that time almost 200 allogenic (unrelated donor) marrow transplants had been performed in humans but with no long-term successes. Then, in 1958, Edward Donnall Thomas made history when he injected bone marrow containing stem cells into a 3 year old leukemia patient that had been harvested from her identical (healthy) twin. The young child did well for six months, but then had a recurrence of her cancer4.
During February 1961, Canadians James E. Till, a biophysicist, and Ernest A. McCulloch, a hematologist, published findings in the journal “Radiation Research” that proved the existence of cells that can self-renew repeatedly also known as “stem cells”. Both worked for the Ontario Cancer Institute (OCI) at the time5.
In 1968, University of Minnesota doctors performed the first ever hematopoietic stem cell transplantation (HSCT) for patients with inherited cellular immunodeficiency conditions: one was a child with severe combined immune deficiency (SCID) and the other a child with Wiskott–Aldrich syndrome (WAS). The donors in both case were matched siblings.6
Then, in 1969, after years of work on histocompatibility and the development of antibiotics that inhibit transplant rejection, Edward Donnall Thomas performed the first successful allogenic (unrelated donor) bone marrow transplants. 7,8
Bone marrow transplantation, of course, proved a powerful way to turn the tables on leukemia, and was also eventually employed to successfully combat a multitude of other diseases including aplastic anemia, Hurler’s syndrome and other inherited metabolic disorders, severe combined immunodeficiency (SCID), sickle cell disease, and Wiskott-Aldrich syndrome9.
Discoveries in stem cell science happened at a fairly rapid clip beginning in the 1970s. I will quickly touch on some of the highlights plus my work with umbilical cord stem cells abroad before focusing attention back on the biological and clinical treasure-trove which is bone marrow.
- In 1978 stem cells were discovered in human umbilical cord blood.
- In 1981 the very first in vitro stem cell line was developed from mice.
- In 1988 embryonic stem cell lines were derived from a hamster and in 1995 the very first embryonic stem cell line was created from a primate.
- In 1997, a lamb was cloned from stem cells and dubbed “Dolly”.
- In 1997 the origins of leukemia was traced to defects in hematopoietic stem cells or cancer stem cells.
- In 1998, James A. Thompson at the University of Wisconsin isolated cells from the inner cell mass of early human embryos and developed the first embryonic stem cell lines. During the same year, John D. Gearhart at Johns Hopkins University, derived germ cells from cells in fetal gonad tissue.
- And in 2006, researchers successfully “reprogrammed” or transformed somatic cells into a stem cell-like state. This new type of stem cell was subsequently called “induced pluripotent stem cells” (iPSCs).
Sources for bullet points above:
By the late 1990s I like many physicians had become keenly aware of the work being done with embryonic stem cells and their purported promise to usher in a new age of regenerative medicine. However, as ethical objections over using embryonic stem cells gained traction and studies appeared showing that these stem cells produce teratomas in lab animals, many researchers and doctors began focusing on adult stem cells.
In order to appreciate the appeal of adult stem cells to doctors like me who were looking for ways to remediate or cure a wide swath of diseases and medical conditions, it helps to understand the type and nature of stem cells that reside in embryos versus those typically found in non-embryonic, somatic tissues:
Embryonic stem cells are pluripotent; that is, they possess the potential to differentiate into any of the three germ layers that give rise to all the organs and such in all of us: endoderm, mesoderm, or ectoderm. This means they can become any fetal or adult cell type. In their native embryonic environment they get a carefully orchestrated series of signals from surrounding tissue that guides them to follow specific developmental pathways in precise ways (A baby results). When these signals are missing, out of their normal order, conflicted or present in the wrong quantities as happens when these embryonic stem cells are implanted in the tissues or organs in animals, they can remain undifferentiated, differentiate into a cell type at odds with the tissue they are engrafted in, or even form a teratoma.
Adult stem cells, which arise after early stage or embryonic development and are found in our organs, plus adipose, dental pulp and many other tissues, are more restricted in terms of the types of bodily cell types they can become. This makes sense as most of these stem cells never leave the tissue or organ they are part of and basically serve to replenish cells that die off as well as promote the repair and regeneration of local tissues that incur damage due to aging, disease, or injury. In addition, stem cells exist in umbilical cord blood & the gelatinous Wharton’s Jelly that surrounds umbilical cord blood vessels, as well as the amnion and amniotic fluid, and placenta. These stem cells are more biologically plastic or versatile than adult stem cells taken from fully developed tissues and organs, yet unlike embryonic stem cells do not form teratomas.
The adult stem cells in most of the body’s organs and tissues tend to be a mix of multipotent, oligopotent and unipotent stem cells. These terms refer to the developmental plasticity or versatility of these stem cells. In-a-word: multipotent stem cells can differentiate into a number of somatic cell types, but only into those of a closely related family of cells. Oligopotent stem cells on-the-other-hand can differentiate into only a few cell types such as lymphoid or myeloid cells, while unipotent cells can generate only one somatic cell type, their own, though they possess the property of self-renewal (which sets them apart from non-stem cells).
General classification of stem cell plasticity (Developmental versatility)
All bodily cell types (e.g., somatic cell types, Germ Cells, etc)
Fertilized egg, Zygote, Morula cells
Adult Totipotent Stem Cells
All somatic cell types, e.g., heart cells, kidney cells, neurons, etc.
Inner Cell Mass (ICM) of Blastocysts
Embryonic Stem Cells
Adult pluripotent stem cells, e.g., from body tissues such as bone marrow, umbilical cord, umbilical cord blood, etc.
Lineage-committed – Germ Layer Lineage Stem Cells
Ectoderm associated stem cells
Mesoderm associated stem cells
Endoderm associated stem cells
Multipotent – Cell specific
Neural stem cells
Cord blood stem cells
Hematopoietic stem cells
Most bone marrow stem cells
Unipotent –Committed to becoming a single cell type
Dopamine expressing neurons
Interestingly, bone marrow tissue and umbilical cord blood contains a wealth of multipotent stem cells including mesenchymal stem cells but also some pluripotent stem cells such as a small number of very small embryonic-like stem cells (VSELs). So why don’t these pluripotent stem cells form teratomas when implanted or infused in animals or people? Apparently they have been exposed to growth factors or other bioactive molecules in the more developmentally advanced tissues they come from that are absent in embryos, and which leave them far less prone to form teratomas.
Like many doctors in countries outside the USA I learned of the pioneering work of Paul Niehans, et al and his transplantation of live fetal tissue transplantations (usually sheep) and was impressed by his reported clinical successes and safety of this treatment approach. These safe and apparently effective treatments preceded and paved the way for clinical work in people using human (nonembryonic) stem cells. Between 1991 and 2001 I worked with a Mexican orthopedic surgeon who used shark embryonic tissues to successfully treat spinal cord injuries.
Armed with this background, and having done an exhaustive review of the published research available at the time plus foreign stem cell patient case histories, it was plain to see that adult stem cells were not only safe but largely effective in terms of producing clinical benefits in a number of diseases and medical conditions in both adults and children. With an eye out for opportunities to wade into the world of stem cell medicine, my orthopedic surgeon colleague in Mexico signaled that he was interested in and had the legal clearance to begin working with pure umbilical cord stem cells in his country. We forged a collaborative agreement and, once he was ready to begin treating patients with cord stem cells, I proceeded to set up a nonprofit research institute bearing my name (Steenblock Research Institute – SRI) in southern California for the purpose, in part, of helping educate and track patient coming from the US and elsewhere for umbilical cord stem cell treatments in Mexico. This was March 2003.
In the years that followed the staff at SRI accumulated response and outcome data on over 1000 patients treated in Mexico. With my participation we also carried out an open label pilot study in Mexico during 2004 in which eight children with cerebral palsy were treated with a subcutaneous injection of 1.5 million CD34+/AC133 umbilical cord stem cells. This study not only revealed statistically significant improvements in a number of bodily functions in the majority of those treated but we also documented a partial resolution of cortical blindness in a 5 year old boy with optic nerve hypoplasia10.
Some of the clinical successes we were seeing in Mexico were laid out in a book I coauthored that came out in 2006 titled “Umbilical Cord Stem Cell Therapy: The Gift of Healing from Newborns” (Basic Health Publishing).
But as wonderful as umbilical cord stem cell therapy had proved-to-be I could not help but wonder what stem cells from a patient’s own fat and bone marrow might do (autologous stem cells). They should, I reasoned, do as well or better than cord because they are autologous and would not be cleared by the patient’s immune system, something that was likely occurring with respect to a large percentage of the allogenic cord blood stem cells being infused in patients in Mexico.
Given my past involvement with bone marrow transplant work at the University of Washington, I naturally gravitated to working with bone marrow stem cells. The big question was a regulatory one: I knew that purifying or processing bone marrow stem cells beyond a certain point with the aim of using the end product in patients would require filing an IND (new drug application) with the FDA and going through the formidable and costly new drug approval process. But what if I merely took bone marrow, spun it down in a centrifuge, removed the top layer (buffy coat) and then administered it to patients?
To get an answer to this I asked my FDA regulations savvy lawyer, Rick Jaffe (J.D., Columbia University School of Law), to query the FDA. Within a few weeks the answer came back: The use of “minimally manipulated” bone marrow was not regulated by the FDA and fell under the practice of medicine.
With this answer in-hand I began working with bone marrow aspirate concentrate or BMAC. This was spring 2005 and since then I have performed over 2000 BMAC treatments.
As the focus of my clinical work in 2005 was turning the tables on neurological conditions such as chronic stroke, I naturally began using BMAC on these sorts of cases.
I knew from my work with umbilical cord stem cells in Mexico that in neurological insults or conditions in which ischemia, hypoxia and/or neuroinflammation was present, biochemical compounds especially the chemokine (cell signaling protein) stromal-derived factor (SDF)-1 is released which acts like a homing beacon to cord blood stem cells11.
Interestingly, various studies done since I began using BMAC in 2005 have shown when inflammation occurs in the brain the sufferers’ bone marrow will mobilize stem cells, some of which make their way through the blood-brain barrier to the inflammation site12,13. Given the existence of this natural mechanism for dealing with inflammation spawned by injury or disease, my use of BMAC amounts to augmentation of a natural process.
By 2010 I had enough patient response information and test results to tell me that my use of BMAC in patients under the age of forty uniformly produced good-to-impressive clinical improvements while virtually the opposite was true in those over forty. The fact these older patients were typically juggling more chronic medical issues than the younger ones accounts for part but not all of their less pronounced clinical responses. Another, far greater contributor was the age-related shift in the proportion stem cell rich red marrow content to yellow, fat-rich and stem cell poor marrow tissue. This might have tempted me to conclude that biology is destiny if it were not for the fact that I had found a reversal in this pattern in older patients who exercised daily by running or walking or spent a great deal of time hiking in the high mountains or who regularly donated blood. They tended to have healthier, more abundant red bone marrow than their less active peers. Not surprisingly, I found that older sedentary people had significantly poorer clinical results when treated with a simple bone marrow transplant (BMAC). I also observed that the bone marrow in people with emphysema, Parkinson’s disease or dementia (as well as many other chronic diseases and medical conditions) had diminished in quantity and quality to the point that most of the cells were senescent!
One way to get old, yellow fat dominated marrow to produce red marrow would, I reasoned, be to use Intermittent Hypoxia Therapy or IHT (which simulates mountain climbing). I had numerous older sedentary patients do IHT (in my clinic) and saw the bone marrow do the expected “color shift”. The presence of more red than yellow bone marrow naturally gave these oldsters a greater complement of healthier “younger” stem cells as well an increase in the numbers of circulating healthy stem cells.
As I thought about ways to turn the tables on this biological reality, I recalled a line of evidence pointing to the fact that if large numbers of stem cells were mobilized from the marrow it would respond by producing fresh, new stem cells that would likely be more vigorous than those had been “purged”. I then did PubMed and other data base searches to check on this and turned up many papers by David T. Scadden§ and his associates at Harvard (dating from roughly 2008 on) that pointed out this very thing and included lab animal evidence supporting it14. However, there were no studies I could locate indicating that bone marrow stem cell mobilization had been used in people for the purpose of gauging whether the vacated stem cell niches would be filled with more pristine, vigorous stem cells. This prompted me to see what would happen if I gave injections of FDA approved colony stimulating factors such as Neupogen® to mobilize bone marrow stem cells especially in older, sedentary people. And, sure enough, the marrow responded by generating abundant new, more vibrant stem cells.
With experimentation I found that large numbers of new stem cells were produced when Neupogen® was given for five (5) consecutive days by injection followed by a two week wait. This was verified by the stem cell biologist at SRI who examined bone marrow samples taken from patients prior to the “Neupogen® purge”, and then again two weeks later following the five day series of Neupogen® injections. He found upwards of ten (10) times more healthy stem cells in the post-purge samples.
Not unexpectedly, older patients who did the Neupogen® purge and then had bone marrow harvested and given back to them as a BMAC treatment did far better than those their age with similar medical problems who’d not undergone the purge. Most had neurological diseases or conditions such as chronic stroke, ALS (Lou Gehrig’s disease), multiple sclerosis, Alzheimer’s and other dementias, or traumatic brain injury.
As the clinical successes mounted I began treating young people with neurological problems such as cerebral palsy, Huntington’s disease and autism. I also found myself increasingly doing BMAC treatments on people with non-neurological issues including people with joint, ocular, cardiac, kidney, respiratory and gastrointestinal diseases and conditions.
Of course, while I labored away at the clinical level with BMAC and found it safe and effective especially with respect to joint and certain neurologic diseases and conditions, the research world was not sitting idle. Well, not exactly anyway. There were a handful of studies designed and carried out that pointed to the fact BMAC is safe and produced significant clinical benefits for specific medical challenges. I’ll summarize two of them:
In 2011 Tufts Medical Center carried out a pilot, multicenter, prospective, randomized, double-blind, placebo-controlled study for “no option” critical limb ischemia (CLI) patients. Thirty-four patients wound up treated with BMAC and 14 received sham injections. There were no adverse events attributed to the injections. Bottom line: The BMAC treated group demonstrated trends toward improvement in amputation, pain, quality of life, Rutherford classification, and ABI (ankle brachial index) compared with controls15.
And in May 2011 Arthroscopy: The Journal of Arthroscopic and Related Surgery published results of a prospective study in which 25 patients (mean age 46 years) with grade IV cartilage lesions of the knee underwent a mini-arthrotomy and concomitant transplantation with BMAC covered with a collagen I/II matrix (Chondro-Gide; Geistlich, Wolhusen, Switzerland), and were then followed for two years. Patients showed significant improvement in all scores on seven evaluative tests at final follow-up (p < .005). In addition, MRI scans revealed good coverage of the lesion and tissue quality in all patients. No adverse reactions or postoperative complications occurred16.
Interestingly, on October 21 of this year (2015) I did a search of the US government clinical studies database at http://clinicaltrials.gov/ using “bone marrow aspirate concentrate” as my search term and turned up seven studies that are actively recruiting patients. Most of these involve BMAC use for various orthopedic and musculoskeletal issues. None of these concern neurologic diseases or conditions.Bottom of Form
The clinical successes I and others have seen with use of autologous BMAC naturally begs the question: How do the stem cells in BMAC work to affect healing and restoration? That is, do the various adult stem cell types present differentiate into the cell types of the tissue they engraft in or in one way or another become cell types that encourage healing and restoration, or do they secrete substances that have a paracrine (cell-to-cell signaling) effect that remediates or heals, or both?
The quick and short answer is “both” which I will now illustrate with information gleamed from a handful of telltale studies:
In 2002 University of Minnesota researchers induced stroke in rats and one (1) week later grafted purified human mesenchymal stem cells (MSCs) into the cortex surrounding the area of infarction. Following sacrifice of the animals, histological analyses revealed that the transplanted human MSCs were expressing biomarkers for astrocytes, oligodendroglia, and neurons. The grafted cells morphological features or appearance, however, was spherical in nature with few of the structures associated with astrocytes and such17.
In 2007 Japanese scientists induced skin wounds in mice and then i.v. injected them with MSCs (derived from mice bred to produce Green Fluorescent Protein [GFP] in their tissues). They detected GFP-positive cells at the wound sites associated with specific markers for various skin cell types such as keratinocytes, endothelial cells, and pericytes. The treatment resulted in accelerated wound repair18.
And in another 2007 study, New York Medical College researchers explored the fate of bone marrow stem cells injected into infarcted (transgenic) mice. The researchers found that the bone marrow stem cells engrafted, survived, and grew within the myocardium by forming connections with resident myocytes (Heart muscle cells). This and a confluence of other evidence showed that the bone marrow stem cells had transdifferentiated, i.e., converted from one cell type to another, and acquired cardiomyogenic and vascular characteristics and traits (phenotypes) that culminated in restoration of the animal’s infarcted hearts19.
Other studies have revealed the transdifferentiation of bone marrow derived stem cells into insulin-producing cells in animal models of diabetes (streptozotocin-induced diabetic mice)20, differentiation of engrafted bone marrow-derived mesenchymal stem cells into specific and distinct lung cell phenotypes in animals with bleomycin-induced pulmonary damage21, and much more.
Many skeptics have pointed out that no matter how many millions of adult stem cells are infused into patients, the numbers that actually engraft and differentiate or transdifferentiate in target tissues or organs is too low to have a major impact on whatever damage or disease is present. This might be true if healing and restoration was dependent on the differentiated or transdifferentiated cells alone. However, both I and many others working in stem cell medicine contend that the infused cells, both those that engraft and those that do not and are eventually cleared or die off, facilitate healing by other means. This brings me to the paracrine and other effects of substances secreted by these cells, a mechanism that in my opinion probably accounts in large part for the remediative, healing and restorative impact seen in the clinic.
During the past decade or so researchers have identified numerous growth factors (plus a chemokine) that are expressed by bone marrow stem cells, typically upon engraftment. These are the principle ones:
Platelet-derived growth factor – PDGF promotes tissue remodeling and cellular differentiation, participates in inductive events involved in patterning and morphogenesis, and promotes angiogenesis.
Vascular endothelial growth factor alpha and vascular endothelial growth factor beta – VEGF-alpha & VEGF-beta both stimulate vasculogenesis and angiogenesis. VEGF also stimulates neurogenesis in vitro and in vivo http://www.pnas.org/content/99/18/11946.full
Transforming growth factors (TGFs) TGFA, TGFB1, TGFB2 and TGFB3 – TGFs are a family of structurally related proteins that control proliferation, differentiation and other functions in many cell types
Bone morphogenetic proteins (BMPs) 1, 2, 3, 4, 6, 7, 8B, R1A, and PR2 – These growth factors have various effects, most being integral to cartilage and bone development plus fracture repair. One, BMP7 is involved in renal development and repair.
Nerve Growth Factor (Bone marrow mesenchymal stem cells) – NGF is a small protein that is important for the differentiation, growth, maintenance, and survival of sensory and sympathetic neurons. It also functions as a signaling molecule.
Source for growth factors listed above: “Growth factors and gene expression of stem cells: bone marrow compared with peripheral blood” http://www.ncbi.nlm.nih.gov/pubmed/20523179
Hepatocyte growth factor (Bone marrow Mesenchymal stem cells)22 – HGF is a paracrine cellular growth, motility and morphogenic factor that targets and acts primarily upon epithelial cells, endothelial cells and also hematopoietic progenitor cells. It has been shown to have a major role in wound healing and adult organ regeneration.
Insulin-like growth factor-123 – IGF-1 binds to the insulin-like growth factor 1 receptor present on many cell types in many tissues. It is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. In addition, IGF-1 is a primary mediator of the effects of growth hormone (GH).
Stromal-derived factor-124 – SDF-1 promotes hematopoietic cell mobilization and migration, among other things.
In addition, adult stem cells have also been found to express various chemokines, bioactive lipids (such as sphingosine-1-phosphate and ceramide-1-phosphate), as well as microRNA also written as miRNA (i.e., small non-coding RNA molecules which act to downregulate gene expression in a variety of ways) and RNA that many researchers feel are primary drivers of tissue and organ regeneration by virtue of paracrine signaling25.
What is especially exciting are findings showing that activated stem cells secrete microvesicles (MVs) or exosomes, which are small, spherical membrane fragments shed from cell surfaces or that are secreted from the endosomal compartment within cells that inhibit programmed die-off (apoptosis) of cells residing in damaged tissues, as well as stimulate their proliferation and promote vascularization26. One research group found that these stem cell-generated MVs “contained ribonucleoproteins involved in the intracellular traffic of RNA and selected pattern of microRNAs, suggesting a dynamic regulation of RNA compartmentalization in MVs. The observation that MV-highly expressed miRNAs were transferred to target cells, raises the possibility that the biological effect of stem cells may, at least in part, depend on MV-shuttled microRNAs”27
In conclusion, I have covered a lot of ground in this article. My goal in this was to use my path into the world of stem cell medicine along with findings from the published science to illustrate the fact that adult stem cells, especially those found in bone marrow, are a powerful therapeutic modality. Whether they work their healing and restorative “magic” because they engraft and transdifferentiate or differentiate into specific cell types, or secrete paracrine and other factors, or both, the fact is they get the job done. They did this for Edward Donnall Thomas and his patients, they have for me and my patients, and they can do this for doctors reading this and their patients.
- Autobiographical entry by Nobel laureate Edward Donnall Thomas, MD on NobelPrize.Org http://www.nobelprize.org/nobel_prizes/medicine/laureates/1990/thomas-autobio.html
- Cell Therapy & Transplantation, Vol. 1 #3, ISSN 1866-8836
“Focus: Maximow 1909 centenary”http://ctt-journal.com/contents_vol1_no3.html
- Ibid, Cell Therapy & transplantation, et al
- Stem Cell History Timeline http://www.stemcellhistory.com/stem-cell-research-timeline/
- Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. Dec 28 1968;2(7583):1366-9.
- Bortin MM. A compendium of reported human bone marrow transplants. Transplantation. Jun 1970;9(6):571-87.
- E. Donnall Thomas biography http://www.nndb.com/people/364/000132965/
- Ibid E. Donnell Thomas biography
- Fernando Ramirez, David Steenblock, Anthony G. Payne and Lyn Darnall, Umbilical Cord Stem Cell Therapy for Cerebral Palsy, F. Ramirez et al (2006), Medical Hypotheses & Res. 3: 679-686. http://www.journal-mhr.com/PDF_Files/vol_3_2/3_2_PDFs/3_2_2.pdf
- SDF-1 (CXCL12) Is Upregulated in the Ischemic Penumbra Following Stroke: Association with Bone Marrow Cell Homing to Injury, Journal of Neuropathology & Experimental Neurology: January 2004 – Volume 63 – Issue 1 – p 84–96 http://journals.lww.com/jneuropath/Abstract/2004/01000/SDF_1__CXCL12__Is_Upregulated_in_the_Ischemic.9.aspx
- “The Great Migration of Bone Marrow-Derived Stem Cells Toward the Ischemic Brain: Therapeutic Implications for Stroke and Other Neurological Disorders” Prog Neurobiol. Author manuscript; available in PMC 2012 October 1. Published in final edited form as:Prog Neurobiol. 2011 October; 95(2): 213–228. Published online 2011 August 30. doi: 10.1016/j.pneurobio.2011.08.005. PMCID: PMC3185169. NIHMSID: NIHMS321777 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185169/
- “Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study” Stem Cell Res Ther. 2010; 1(2): 17. Published online 2010 June 15. doi: 10.1186/scrt17 PMCID: PMC2905093
- Lymperi, S., Ferraro, F., & Scadden, D. T. (2010). The HSC niche concept has turned 31 Has our knowledge matured? Annals of the New York Academy of Sciences, 1192, 12–18. http://doi.org/10.1111/j.1749-6632.2009.05223.
- Iafrati MD, Hallett JW, et al, ‘Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia’, J Vasc Surg. 2011 Dec;54(6):1650-8. Epub 2011 Oct 21. http://www.ncbi.nlm.nih.gov/pubmed/22019148
- Alberto W. Gobbi, Georgios Karnatzikos, Vivek Mahajan, ‘The Use of Bone Marrow Aspirate Concentrated for Full-thickness Knee Cartilage Lesions in a One-step Procedure: A Prospective Study (SS-25)’, Arthroscopy: The Journal of Arthroscopic and Related Surgery, Volume 27, Issue 5, Supplement , Page e43, May 2011 http://www.arthroscopyjournal.org/article/S0749-8063(11)00246-5/abstract
- Li-Ru Zhao, Wei-Ming Duan, et al, ‘Human Bone Marrow Stem Cells Exhibit Neural Phenotypes and Ameliorate Neurological Deficits after Grafting into the Ischemic Brain of Rats’, Experimental Neurology, Volume 174, Issue 1, March 2002, Pages 11–20
- Sasaki M, Abe R, Fujita Y, et al, ‘Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type’, J Immunol. 2008 Feb 15;180(4):2581-7.
- Rota M, Kajstura J, Hosoda T, Bearzi C, et al, ‘Bone marrow cells adopt the cardiomyogenic fate in vivo’, Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17783-8. Epub 2007 Oct 26.
- Tang DQ, Cao LZ, et al, ‘In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow’, Diabetes. 2004 Jul;53(7):1721-32.
- Mauricio Rojas, Jianguo Xu, Charles R. Woods, et al, ‘Bone Marrow–Derived Mesenchymal Stem Cells in Repair of the Injured Lung’, Am J Respir Cell Mol Biol. 2005 August; 33(2): 145–152. Published online 2005 May 12. doi: 10.1165/rcmb.2004-0330OC PMCID: PMC2715309. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715309/
- Weimar IS, Miranda N, Muller EJ, et al, ‘Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+).’, Exp Hematol. 1998 Aug;26(9):885-94.
- Takahashi M, Li TS, Suzuki R, et al, ‘Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury’, Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H886-93. Epub 2006 Apr 7. http://ajpheart.physiology.org/content/291/2/H886.short
- Zhang M, Mal N, Kiedrowski M, et al, ‘SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction’, FASEB J. 2007 Oct;21(12):3197-207. Epub 2007 May 11. http://www.fasebj.org/content/21/12/3197.full.pdf+html
- MZ Ratajczak, M Kucia, T Jadczyk, NJ Greco, et al, ‘Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies?’, Leukemia (2012) 26, 1166 – 1173, http://126.96.36.199:9998/91keshi/Public/File/47/26-6/pdf/leu2011389a.pdf
- Ibid, pg 1166
- Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, et al. (2010) ‘Microvesicles Derived from Adult Human Bone Marrow and Tissue Specific Mesenchymal Stem Cells Shuttle Selected Pattern of miRNAs’, PLoS ONE 5(7): e11803. doi:10.1371/journal.pone.0011803http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0011803
- David T. Scadden, MD is Gerald and Darlene Jordan Professor of Medicine at Harvard University, founder and director of the Center for Regenerative Medicine at the Massachusetts General Hospital and with Douglas Melton, co-founder and co-director of the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology.
This article is a revised version of text from a presentation Dr. Steenblock gave at the “Europas größter Ärztekongress für Komplementärmedizin” (translated “Europe’s largest medical conference on complementary medicine”) in November 2012
© 2015 by David A. Steenblock, D.O., Inc. All rights reserved.
ABOUT DR. STEENBLOCK
Dr. David A. Steenblock earned his B.S. degree from Iowa State University, then an M.S. in biochemistry and Doctor of Osteopathy (D.O.) degree from the College of Osteopathic Medicine and Surgery in Des Moines, Iowa. His post-doctoral training included three years at Case Western Reserve University, one year at the Oregon Health & Sciences University and a clinical Rotating Internship at Providence Hospital in Seattle, Washington.
During the late 1970s he founded the first integrative medicine clinic west of the Mississippi River. In the years since he has done pioneering clinical work including the use of hyperbaric oxygen therapy to treat stroke (starting in 1989), umbilical cord stem cell therapy (Mexico from 2003) and, since 2005, stem cell rich bone marrow aspirate concentrate (BMAC).
In October of 2015 he was awarded the Academy of Comprehensive Integrative Medicine’s (ACIM) “Lifetime Achievement Award” at their NeuroRegeneration Conference (Orlando, Florida) in recognition of his more than forty years of contributions “to the betterment of mankind and the advancement of integrative medicine”.
While at the ACIM conference, Dr. Steenblock gave a presentation on Amyotrophic Lateral Sclerosis (ALS) or “Lou Gehrig’s disease” that included data and insights gleamed from an observational study he did of 54 sporadic ALS patients he treated over a four year period (2011-2015). He shared evidence he found in the majority (52 of 54 sALS patients) that links spinal injury and subsequent reinjury to breaches in the blood-cerebrospinal barrier; breaches which then admit specific neurotoxic compounds, activated and damaged immune cells that secrete misfolded SOD1, as well as other cell and nerve cell toxic players (Some of which are selectively lethal to motor neurons). He also discussed his use of bone marrow stem cells and other means to repair these breaches, offset and reverse the damage, and counter the ALS disease process.
The spinal injuries/reinjuries and the symptoms and pathological damage Dr. Steenblock discovered provides both a unique risk factor and biomarker for sALS. If validated by subsequent research, this is something physicians and researchers can use to better diagnose sALS.
A paper concerning this has been prepared for submission to a top tier peer reviewed journal devoted to ALS.